These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 9887238)

  • 21. Involvement of annexin V in antiproliferative effects of gonadotropin-releasing hormone agonists on human endometrial cancer cell line.
    Shibata S; Sato H; Ota H; Karube A; Takahashi O; Tanaka T
    Gynecol Oncol; 1997 Aug; 66(2):217-21. PubMed ID: 9264565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Localization of matrix metalloproteinases on endometrial cancer cell invasion in vitro.
    Park DW; Ryu HS; Choi DS; Park YH; Chang KH; Min CK
    Gynecol Oncol; 2001 Sep; 82(3):442-9. PubMed ID: 11520138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitory effect of luteinising hormone-releasing hormone analogues on human endometrial cancer in vitro.
    Noci I; Coronnello M; Borri P; Borrani E; Giachi M; Chieffi O; Marchionni M; Paglierani M; Buccoliero AM; Cherubini A; Arcangeli A; Mini E; Taddei G
    Cancer Lett; 2000 Mar; 150(1):71-8. PubMed ID: 10755389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
    Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
    Clin Cancer Res; 2005 Aug; 11(15):5549-57. PubMed ID: 16061872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro evaluation of the growth inhibition and apoptosis effect of mifepristone (RU486) in human Ishikawa and HEC1A endometrial cancer cell lines.
    Navo MA; Smith JA; Gaikwad A; Burke T; Brown J; Ramondetta LM
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):483-9. PubMed ID: 18004570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation.
    Engel JB; Honig A; Schönhals T; Weidler C; Häusler S; Krockenberger M; Grunewald TG; Dombrowski Y; Rieger L; Dietl J; Wischhusen J
    Eur J Obstet Gynecol Reprod Biol; 2008 Nov; 141(1):64-9. PubMed ID: 18687514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transforming growth factor-alpha and insulin-like growth factor-I, but not epidermal growth factor, elicit autocrine stimulation of mitogenesis in endometrial cancer cell lines.
    Reynolds RK; Hu C; Baker VV
    Gynecol Oncol; 1998 Aug; 70(2):202-9. PubMed ID: 9740691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GnRH agonist therapy in human ovarian epithelial carcinoma (OVCAR-3) heterotransplanted in the nude mouse is characterized by latency and transience.
    Peterson CM; Jolles CJ; Carrell DT; Straight RC; Jones KP; Poulson AM; Hatasaka HH
    Gynecol Oncol; 1994 Jan; 52(1):26-30. PubMed ID: 8307497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53 interference and growth inhibition in p53-mutant and overexpressing endometrial cancer cell lines.
    Janicek MF; Angioli R; Unal AD; Sevin BU; Madrigal M; Estape R; Averette HE
    Gynecol Oncol; 1997 Jul; 66(1):94-102. PubMed ID: 9234928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of gastrin-releasing peptide receptors in endometrial cancer.
    Levine L; Licci JA; Townsend CM; Hellmich MR
    J Am Coll Surg; 2003 Jun; 196(6):898-904. PubMed ID: 12788426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The expression and action of granulocyte macrophage-colony stimulating factor and its interaction with TGF-beta in endometrial carcinoma.
    Ripley D; Tang XM; Ma C; Chegini N
    Gynecol Oncol; 2001 May; 81(2):301-9. PubMed ID: 11330966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines.
    Emons G; Ortmann O; Becker M; Irmer G; Springer B; Laun R; Hölzel F; Schulz KD; Schally AV
    Cancer Res; 1993 Nov; 53(22):5439-46. PubMed ID: 8221683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longstanding survival without cancer progression in a patient affected by endometrial carcinoma treated primarily with leuprolide.
    Noci I; Borri P; Bonfirraro G; Chieffi O; Arcangeli A; Cherubini A; Dabizzi S; Buccoliero AM; Paglierani M; Taddei GL
    Br J Cancer; 2001 Aug; 85(3):333-6. PubMed ID: 11487260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of GnRH analogs on six ovarian cancer cell lines in culture.
    Connor JP; Buller RE; Conn PM
    Gynecol Oncol; 1994 Jul; 54(1):80-6. PubMed ID: 8020844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of luteinizing hormone releasing hormone and its mRNA in human endometrial cancer cell lines.
    Irmer G; Bürger C; Ortmann O; Schulz KD; Emons G
    J Clin Endocrinol Metab; 1994 Sep; 79(3):916-9. PubMed ID: 8077383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gonadotropin-releasing hormone type II induces apoptosis of human endometrial cancer cells by activating GADD45alpha.
    Wu HM; Cheng JC; Wang HS; Huang HY; MacCalman CD; Leung PC
    Cancer Res; 2009 May; 69(10):4202-8. PubMed ID: 19366794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell cycle arrest in endometrial carcinoma cells exposed to gonadotropin-releasing hormone analog.
    Kim JW; Lee YS; Kim BK; Park DC; Lee JM; Kim IK; Namkoong SE
    Gynecol Oncol; 1999 Jun; 73(3):368-71. PubMed ID: 10366462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significant anti-proliferation of human endometrial cancer cells by combined treatment with a selective COX-2 inhibitor NS398 and specific MEK inhibitor U0126.
    Gao J; Niwa K; Takemura M; Sun W; Onogi K; Wu Y; Seishima M; Mori H; Tamaya T
    Int J Oncol; 2005 Mar; 26(3):737-44. PubMed ID: 15703831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Intermediate-conductance-Ca2+-activated K+ channels are overexpressed in endometrial cancer and involved in regulating proliferation of endometrial cancer cells].
    Wang ZH; Feng YJ; Su M; Yi XF
    Zhonghua Fu Chan Ke Za Zhi; 2007 Feb; 42(2):111-5. PubMed ID: 17442186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.